FDA approves world's first RSV vaccine for adults 60 and up

The US FDA has approved the world's first vaccine against respiratory syncytial virus (RSV), a respiratory illness that can be life-threatening for young children, the elderly, and those with underlying health conditions. The vaccine, named Arexvy by manufacturer GSK, still needs approval from the US Centers for Disease Control and Prevention before it can be rolled out to the public. It could be available to people over 60 within months, officials say. RSV kills thousands of Americans each year and the vaccine is a major breakthrough that will save many lives.